Introduction
============

Nanotheranostics, interwoven with both diagnostic and therapeutic functions, can achieve accurate tissue targeting and optimal treatment efficacy for many diseases, especially for cancer management [@B1], [@B2]. As for cancer diagnosis, PA imaging collects photon-triggered acoustic signals and non-invasively constructs tumor images with reasonably high resolution [@B3]-[@B9]. In particular, ratiometric PA imaging based on activatable probes, with ultrasensitive detection of tumor biomarkers and minimal interference of endogenous PA contrast, can achieve much higher signal-to-noise ratio than conventional "always on" probes [@B10]-[@B14]. Recently, a variety of ratiometric PA probes have been successfully developed and applied for accurate detection of reactive oxygen species (ROS), hypoxia, and pH in the tumor microenvironment (TME), which highly promoted the application of ratiometric PA imaging in biomedicine [@B10], [@B15], [@B16].

For cancer therapy, chemotherapeutics, such as doxorubicin (DOX), gemcitabine and cisplatin, have shown effective antitumor efficacy in the clinic [@B17]-[@B19]. In order to simultaneously maximize the therapeutic effectiveness and minimize the systemic toxicity of free chemotherapeutics, a number of functional nanocarriers, such as polymer micelles and nanovesicles [@B20]-[@B22], have been designed for tumor-specific drug delivery. Especially, the nanocarriers featured with TME stimuli (*e.g.*, higher ROS level, reducibility, hypoxia, or acidity)-responsive drug releases have attracted extensive attention. As we know, acidity is a general hallmark of cancer due to its inordinate metabolism. The pH of normal tissue is about 7.3-7.5, whereas those of tumor tissue and their endosomes and lysosomes are 6.5-7.2 and 4.0-6.0, respectively [@B23]-[@B26]. The pH gradient allows for the design of acidity-responsive drug release system for precise drug release and on-demand chemotherapy. Furthermore, the detection of acidic TME with pH activatable imaging probes is beneficial to effectively monitor the drug release, based on the molecular imaging signal changes [@B27]-[@B33]. Nowadays, the development of activatable PA probes is still at the preliminary stage, which can only be used for imaging tumor biomarkers, but are seldomly used to monitor the drug release, due to the limitations of the molecular structure of PA probe. Therefore, it is of essential importance to develop smart nanotheranostics that allow simultaneous acidic TME-responsive ratiometric PA imaging and real-time cancer chemotherapy monitoring.

Recently, organic semiconducting nanoparticles have received extensive interests due to their excellent PA contrast performance [@B34]-[@B42]. These nanoparticles consist of soft electron-rich materials with strong near-infrared (NIR) absorption, such as conjugated polymers and π-conjugated small molecules. PDI is a typical kind of small semiconducting molecules that can be used for PA imaging for detecting tumor, thrombi and lymph nodes [@B43]-[@B46]. The lone pair electrons of amine act as an electron donor to the acceptor PDI, which causes a redshift of its absorption from 530 nm to 680 nm for excellent PA contrast. On the contrary, the compromise of electron donation from amine group to PDI aromatic ring is expected to induce a blue shift of absorption and quenching of PA signals in the near-infrared region [@B47]. Herein, we report a pH-sensitive nanotheranostic agent consisting of an acid-responsive amine-substituted PDI derivative, a pH insensitive NIR dye (IR825), and an anti-cancer drug DOX (**Figure [1](#F1){ref-type="fig"}**). Based on charge transfer mechanism, the acidity-responsive pH indicator PDI was designed by introducing N-methyl piperazine to PDI bay position to realize a strong 680 nm absorption under neutral condition, which can be weakened according to the degree of protonation of the tertiary amine group at lower pH. Moreover, the π plane and hydrophobicity of PDI facilitate the efficient encapsulation of hydrophobic DOX [@B48]. The protonation of PDI also can speed up the DOX release by increasing the hydrophilicity of PDI. Besides, the hydrophobic IR825 with pH irrelevant absorption peak at 825 nm can be encapsulated by PDI, which acts as an internal reference of the ratiometric PA probe. Therefore, the pH-sensitive nanotheranostic agent could not only specifically image the tumor region and map its pH, but also allow on-demand drug release to effectively inhibit tumor growth.

Results and Discussion
======================

Fabrication of PDI based theranostics
-------------------------------------

In this study, the HPDI and APDI were synthesized to compare their pH sensitivity and drug release characteristics (**Figure [S1](#SM0){ref-type="supplementary-material"}-S10**). The HPDI and APDI own different substituents on the PDI\'s aide position, which are hydroxyl groups and alkyl chains, respectively. The hydrophobic group of the amide position of PDI is expected to reduce the PDI\'s pH sensitivity and inhibit premature release of the encapsulated drugs. In our experiments, the HPDI based nanoagent was shown to be an ideal platform for concurrent ratiometric PA imaging and drug release monitoring. THPDINs, consisting of DOX, HPDI (a pH indicator), and IR825 dye (a pH inert PA matrix), was synthesized by a nanoprecipitation method (**Figure [2](#F2){ref-type="fig"}a**). These three components could be self-assembled into a nanoparticle through hydrophobic interactions and π-π stacking at neutral pH. After the assembly, the PEG~2000~ in the amphiphilic PDI structure endows the theranostic nanoagent with high water solubility and biocompatibility. TEM images revealed the morphology evolution of the THPDINs at different pH values (**Figure [2](#F2){ref-type="fig"}b**). When the pH decreased from 7.4 to 6.5, the quaternized PDI aggregates changed from tight to loosened structures, inducing a relatively bigger particle size. At pH 5.5, a majority of DOX and PDI in the particle turned out to be hydrophilic, resulting in deformation of the nanoparticles. DLS showed that the average diameter of the THPDINs changed from 90 ± 6 nm to 184 ± 15 nm and finally to 519 ± 30 nm (**Figure [2](#F2){ref-type="fig"}c**). The THPDINs was stable in PBS solution (**Figure [S11](#SM0){ref-type="supplementary-material"}**). In comparison with THPDINs, TEM and DLS results of the APDINs (**Figure [S12](#SM0){ref-type="supplementary-material"}-S13**) retained a relatively stable nano size and spherical morphology at pH 5.5, which indicated that the alkyl chain along with π plane of PDI caused serious aggregation and lowered the pKa constant of the alkyl-based PDI structure. Thus, these results suggest that HPDI has high sensitivity of morphology changes in response to a low pH, presumably due to the fact that hydroxyl group increased the hydrophilicity of the perylene core, promoted the hydrogen proton access to the tertiary amine on the bay position, and therefore boosted the quaternization of PDI under weak acidity. The high pH sensitivity featured HPDI a unique platform that can sense low pH and simultaneously release its encapsulated drugs.

Photophysical Properties of PDI based theranostics
--------------------------------------------------

To better understand the role of protonation of the N-methylpiperazine group in the HPDI, density functional theory (DFT) calculations were conducted based on Gaussian 09 [@B49]. The geometries of the pH-sensitive PDI structure and the reaction product of PDI with proton were optimized by B3LYP method basis sets. The optimized geometries showed planar perylene diimide cores on ground-stated geometry (S0), which facilitated π-π stacking and drug loading in water. In the molecular structure of N-methylpiperazine based PDI, the HOMO and LUMO frontier molecular orbitals were delocalized throughout the PDI core (**Figure [3](#F3){ref-type="fig"}a**). However, after protonation of N-methylpiperazine, the LUMO of the PDI structure was localized on the protonated N-methylpiperazine, which led to a non-conjugated electronic cloud on PDI core. This disturbed electronic cloud might explain the blue shift of the UV-vis absorption after protonation of PDI structure.

The absorption of the PDIs and PDI-based ratiometric PA imaging platform was systematically investigated. The absorption of the as-synthesized HPDI and APDI were first measured in different solvents (**Figure [S14](#SM0){ref-type="supplementary-material"}**), which showed strong absorption peaks at around 700 nm and a redshift tendency in the polar solvents. In a neutral solution (**Figure [S15](#SM0){ref-type="supplementary-material"}**), the amphiphilic HPDIs formed nanoparticles with strong absorption at 680 nm, which was an appropriate excitation wavelength for PA imaging. To fabricate the ratiometric PA probe, we selected IR825 dye as a standard probe with no absorption at 680 nm. The IR825 showed pH-independent and robust absorption at around 825 nm within the pH range of 3.0-8.0 (**Figure [S16](#SM0){ref-type="supplementary-material"}**), which has also been verified by previous reports [@B50]-[@B52]. The optical properties of the PDI nanoparticles were measured at different pH values in PBS. The absorption of HPDI nanoparticles (HPDINs) at 680 nm showed high sensitivity to pH change from 7.4 to 5.0, whereas APDINs showed no response to acidity (Figure [3](#F3){ref-type="fig"}b). These observations demonstrated that the hydrophobicity on the amide position of APDI was a key factor for repelling accessibility of water molecules to the bay position and inhibiting the protonation of N-methylpiperazine. The protonation of HPDI was also demonstrated by the reversible zeta potential between pH 7.4 and 5.0 (**Figure [S17](#SM0){ref-type="supplementary-material"}**). Therefore, HPDI was chosen for pH-responsive PA imaging. After the encapsulation of the hydrophobic IR825 and DOX, the absorption of the THPDINs was investigated (**Figure [3](#F3){ref-type="fig"}c**). With decreasing pH, the absorption peak descended at 680 nm but remained the same at 825 nm. Based on the spectra, we also observed that the absorption at 500 nm increased, and the color of the solution changed from brown to red (shown in the inset pictures) with the pH decreased from 7.4 to 5.0, which illustrated that the DOX was also protonated at low pH environment and changed from aggregation to dispersion state. Therefore, based on the pH-responsive UV-vis absorption spectra of THPDINs, the ratio of Ab~825~/Ab~680~ was quantified to be a function of pH value (**Figure [S18](#SM0){ref-type="supplementary-material"}**). The ratiometric absorption signal of Ab~825~/Ab~680~ at pH 5.0 was 2.21-fold and 1.76-fold higher than those at pH 7.4 and 6.5, respectively. This indicated that the well-designed ratiometric probe could accurately differentiate the normal physiological pH (7.4) and the pathological tumor pH (5.0 and 6.5) (**Figure [3](#F3){ref-type="fig"}c**).

The quantitative determination of drug release was obtained by measuring the UV-vis spectrum of DOX outside dialysis tubes (**Figure [3](#F3){ref-type="fig"}d**). The drug loading content of DOX was quantified to be as high as 18.4% and 20.6% to HPDINs and APDINs, respectively. The fluorescence intensity of DOX at pH 7.4 was very weak, which was attributed to the aggregation-induced fluorescence emission quenching and fluorescence resonance energy transfer (FRET) from DOX to PDI [@B53]. However, the fluorescence of DOX was significantly recovered upon acidification of the solution to pH 5.0 (**Figure [S19](#SM0){ref-type="supplementary-material"}**). Compared with the DOX release profile of THPDINs, the control group of DOX-loaded APDINs showed a prolonged DOX release (**Figure [S20](#SM0){ref-type="supplementary-material"}**), which maybe because the strong π-π stacking of the planar PDI cores together with the hydrophobic alkyl side chains effectively trapped DOX in the APDINs. Therefore, the ratiometric absorption of PDI and IR825 could reflect the DOX release at different pH solutions. The performance of THPDINs in PA imaging of pH was evaluated in the solutions of various pH values. The PA/US images of the THPDINs solutions were recorded at the wavelengths of 680 nm and 825 nm at three biologically relevant pH values (**Figure [3](#F3){ref-type="fig"}e**). The PA intensity at 825 nm was stable regardless of pH changes, while the relative intensity at 680 nm decreased from around 1 to 0.4 when pH changed from 7.4 to 6.5 and 5.0 (**Figure [3](#F3){ref-type="fig"}f**). A ratiometric PA value (PA~825~/PA~680~) was calculated based on the ratio of PA intensities at the two wavelengths. The ratiometric PA signal at pH 5.0 was 5.7 ± 0.35, which was around 1.77- and 2.38-fold higher than those at pH 6.5 (3.22 ± 0.27) and 7.4 (2.4 ± 0.17), respectively. From the drug release curve of THPDINs, we could obtain the drug release of 15%, 32%, and 62%, which quantitatively correspond to the ratiometric PA signals under pH 7.4, 6.5, and 5.0 at 24 h, respectively. Good linearity between the ratiometric signal and pH was presented within the range of pH 7.4 to 5.0 (**Figure [3](#F3){ref-type="fig"}g**), indicating that the fitted line can be potentially used as the standard curve to quantify pH *in vivo.*

*In vitro* Drug Delivery Studies
--------------------------------

To observe the DOX release from THPDINs *in vitro*, the confocal fluorescence images were acquired after incubation of THPDINs with U87MG cells for 0.5, 2 or 6 h. Upon incubation with THPDINs for 0.5 and 2 h, red fluorescence signal mainly appeared in the cytoplasm of U87MG cells, indicating that the THPDINs were gradually uptaken by cells and the encapsulated DOX was protonated (**Figure [4](#F4){ref-type="fig"}a**). With the extension of the culture period to 6 h, the DOX was localized in the nucleus and the red fluorescence intensity in cells remarkably increased as well (**Figure [S21](#SM0){ref-type="supplementary-material"}**). The results confirmed that the pH-responsive PDI theranostic platform could be uptaken by U87MG cells and the released DOX can arrive at the nucleus. The quantification of DOX intensity in the cells at different time points also demonstrated the extensive DOX release in cancer cells (**Figure [4](#F4){ref-type="fig"}b**). The cytotoxic effect of the THPDINs on U87MG cells was further evaluated by using MTT assay (**Figure [4](#F4){ref-type="fig"}c**). APDINs and HPDINs showed no toxicity to U87MG cells (**Figure [S22](#SM0){ref-type="supplementary-material"}**), indicating good biocompatibility of the PEG~2000~ linked PDIs. Also, we detected apoptosis in U87MG cells after the treatment with THPDINs. As a result, an increased percentage of apoptotic cells was found with the concentration increased (**Figure [4](#F4){ref-type="fig"}d**), suggesting promising application potentials of our designed THPDINs platform for cancer therapy.

*In vivo* PA investigation of PDI based theranostics
----------------------------------------------------

To demonstrate the feasibility of THPDINs for the ratiometric PA imaging of tumor pH *in vivo*, THPDINs (10 μL, 5 mg mL^-1^) were first locally administered into mice normal tissue after changing the subcutaneous pH value *via* injection of 25 μL of citric buffer (pH 5.0) or NaHCO~3~ solution (pH 8.0). PA signals at 680 and 825 nm were measured at the two artificial pH environments (**Figure [S23](#SM0){ref-type="supplementary-material"}**). The PA signal at 825 nm remained unchanged at different pH values. However, the PA signal at 680 nm was much weaker at pH 5.0 than that at pH 8.0, indicating that PDI was protonated at low pH. The specific ratiometric signal change could easily be distinguished from the PA images. ΔPA was defined as true PA signal of probes with a deduction of the endogenous PA intensity to minimize the tissue interference. The ratiometric PA signal ratio (ΔPA~825~/ΔPA~680~) of the THPDINs at pH 5.0 (4.8 ± 0.5) was about 2-fold higher than that at pH 8.0 (2.4 ± 0.4). The significantly intensified ratiometric PA signal of THPDINs in acidic tissue environment suggested its ability to probe the tumor pH. To visualize the ratiometric PA image of tumor pH and trace chemotherapeutics *in vivo*, THPDINs (200 μL, 5 mg mL^-1^) were intravenously injected into the U87MG tumor-bearing mice. The PA images at the wavelengths of 680 and 825 nm were performed using pseudo green and red colors, respectively (**Figure [5](#F5){ref-type="fig"}a**). The PA signal increment at 825 nm (ΔPA~825~) in the THPDIN-treated mice was substantially increased owing to the EPR effect of the theranostics. However, the increase of ΔPA~680~ was much less than that of ΔPA~825~, which was attributed to the acidic TME-induced protonation of the HPDIs (**Figure [5](#F5){ref-type="fig"}b**). As seen from the obtained PA images of the treated mice, the ratiometric PA signal ratio (ΔPA~825~/ΔPA~680~) gradually increased and reached its maximum at \~24 h post-injection (4.36 ± 0.54, **Figure [5](#F5){ref-type="fig"}c**), which was ∼1.74-fold higher than that at 2 h post-injection (2.5 ± 0.23). These data not only validated that the theranostic THPDINs could reflect the pH in tumor region but also indicated that the ratiometric imaging could monitor the drug release *in vivo*.

*In Vivo* Therapeutic Efficacy of PDI Based Theranostics
--------------------------------------------------------

The promising PA imaging results encouraged us to further evaluate the antitumor efficacy of the THPDINs. U87MG tumor mice were randomly divided into five groups, which were administered with PBS, free DOX, HPDINs, DOX-loaded APDINs, and THPDINs, respectively. The mice treated with PBS, HPDINs, and DOX-loaded APDINs exhibited rapid tumor growth (**Figure [6](#F6){ref-type="fig"}a**), indicating negligible tumor inhibition by using those control materials. The free DOX treated mice showed a slower tumor growth rate in comparison to the PBS control. THPDINs could effectively inhibit the tumor growth and showed higher anticancer efficacy than free DOX *in vivo*. The survival of the THPDINs-treated mice was also much longer than the other control groups (**Figure [6](#F6){ref-type="fig"}b**). No significant body weight loss was observed during the treatment (**Figure [S24](#SM0){ref-type="supplementary-material"}**), indicating that the theranostic platform of THPDINs exhibited high biocompatibility and caused little to no side effects. In addition, the H&E stained tumor sections showed extensive tumor cell apoptosis and necrosis after the treatment of THPDINs, which further validated the outstanding anticancer effect of the THPDINs (**Figure [6](#F6){ref-type="fig"}c**). These results suggested that DOX-loaded pH-responsive PDI produced remarkable inhibitory effect on tumor growth. H&E staining of the heart, liver, spleen, lung and the kidneys of the mice in these experiments did not show any necrosis 7 days after the material injections (**Figure [S25](#SM0){ref-type="supplementary-material"}**). These results demonstrated that the treatment of THPDINs did not observe acute toxicity to the mice.

Conclusions
===========

In conclusion, we developed a multifunctional nanotheranostics for concurrent noninvasive real-time ratiometric PA imaging of tumor acidic pH and monitoring of drug release in living mice. The intriguing HPDI structures were successfully designed and systemically characterized. In the acidic solution, HPDI structure was protonated and went through a hydrophilic structural change to release the encapsulated DOX accompanying with PA signal changes. By further incorporation of a pH inert IR825 dye, a ratiometric PA theranostic platform can be fabricated through self-assembly of the three components. Our designed theranostic platform provides a concept that noninvasive PA imaging signals could monitor tumor-specific pH-responsive drug release. This strategy sheds light on the development of smart activatable theranostic nanoplatforms and will greatly advance the application of new generation of PA theranostics in biology and medicine.

Experimental Section
====================

Materials and Characterization
------------------------------

### Chemicals

All solvents and chemicals were purchased from Sigma-Aldrich (St. Louis, MO), and used without further purification. Pure water was supplied by Milli-Q Plus System (Millipore Corp., Bedford, MA).

### Methods

^1^H NMR spectra were obtained on Bruker Ultra Shield Plus 300 MHz, using CDCl~3~, DMSO-6d as the solvent. The nanoparticles morphology was obtained by TEM images (a JEOL TEM 2010 electron microscope at an acceleration voltage of 100 kV). UV-vis spectra were obtained on a SHIMADZU UV-2501 spectrophotometer. DLS was performed on the Malvern Zeta Sizer Nano S. Confocal laser scanning microscopy was conducted on a Zeiss LSM 780. PA spectra and PA/US images were performed by a LAZR instrument (Visualsonics, 2100 High-Resolution Imaging System). Endra Nexus128 PA tomography system (Endra Inc., Ann Arbor, Michigan) was also used in this study.

### Preparation of PDI nanoparticles (PDINs)

Amphiphilic PDIs was dissolved in THF (2 mL). The PDINs was prepared by dropping excess water (5 mL) into the solutions under sonication at 40 °C. THF was removed through slow evaporation at 50 °C and the resultant PDINs were collected and concentrated by ultrafiltration.

### Preparation of THPDINs (DOX loaded APDINs using the same procedure)

4 mg DOX and 12 mg HPDI was firstly deprotonation by dissolving in THF/MeOH (100:1, volume ratio) with equivalent triethylamine. The IR825 THF solution was prepared in advance, briefly, 1 mg IR825 was firstly dissolved in 10 μL MeOH to get a suspension liquid. Then 5 mL THF was added to the suspension with strong sonication. Finally, the clarified IR825 solution was obtained. Those prepared THF/MeOH solution of HPDI (12 mg), IR825 (0.05 mg) and DOX (4 mg) were mixed to 2 mL. The nanoparticles were formed by dropping 5 mL water into above THF/MeOH solution. Subsequently, THF/MeOH was removed by slow evaporation at 50 °C, and the THPDINs solution was condensed by Amicon Ultra centrifugal filters (10 kDa). The final nanoparticles were concentrated in 10 mmol PBS and filtered through a 0.22 μm filter. The THPDIN solution was lyophilized and resolved in DMF to evaluate the loading content. The absorption of DOX was obtained by subtracting the absorption of PDI at 500 nm. The loading content was calculated by the following equation: weight of encapsulated DOX/weight of DOX loaded PDI nanoparticles\*100 %. Weight of encapsulated DOX was measured by UV-vis spectra.

### *In vitro* drug release property of DOX loaded PDI solution

1 mL DOX loaded PDI solution was filled into dialysis tubing (MW, 2500), which was then sealed and immersed in 5 mL PBS buffer (pH 7.4) and sodium acetate buffer (pH 5.0), respectively. The dialysis system was incubated in water bath at 315 K with vigorous stirring. At designated time points, the buffer was extracted to quantify the amount of released DOX, and then another 5 mL fresh corresponding buffer was supplemented to the dialysis system for further study. The concentration of released DOX was measured by UV-Vis absorption spectra.

### *In vitro* cytotoxicity of THPDINs

MTT assay was performed to investigate the cytotoxicity of PBS, free DOX, HPDINs, DOX loaded APDINs and THPDINs. U87MG cells were seeded on a 96-well plate at a density of 5,000 cells per well and cultured at 37 °C, 5% CO~2~ for 24 h. Then, culture media was replaced by media containing different concentrations of PBS, free DOX, HPDINs, DOX loaded APDINs and THPDINs. The cells treated with different solution were incubated at 37 °C, 5% CO~2~ for 48 h. Then, the medium was replaced with 100 µL fresh medium and 10 µL MTT (5 mg mL^-1^ in PBS) for another 4 h incubation. The MTT medium was replaced with DMSO (100 µL) and the absorbance of each well was measured at 570 nm by microplate reader.

### Cellular imaging by confocal microscopy

The U87MG cells were seeded at a density of 25,000 cells per well in 8-well Lab-Tek cover glass slides. THPDINs were incubated with cells for 0.5, 2 and 6 h, followed by washing with PBS. Cells were stained with mounting medium with DAPI and WGA488 for 30 min. The stained cells were observed with a confocal fluorescence microscope (Zeiss LSM 780).

### *In vitro* and *in vivo* PA imaging

For the *in vitro* experiments, the PDI solutions at different concentrations were filled into polyethylene 50 capillaries. A container was filled with 1% agarose gel to bury the tubes mentioned above testing under Visual Sonic Vevo 2100 LAZR system (40 MHz, 256-element linear array transducer), the wavelength of the laser was chosen from 680 nm to 900 nm. For the *in vivo* local PA imaging, 25 μL of citric buffer (pH 5.0) or NaHCO~3~ solution (pH 8) pretreated the subcutaneous muscle with different pH. Then, THPDINs solution was injected into that environment to obtain ratiometric PA signals by Visual Sonic Vevo 2100 LAZR system. The PA imaging of tumor environment was obtained by *i.v.* injection of THPDINs to U87MG tumor bearing mice under Endra Nexus128 PA tomography system. The quantified PA intensities were obtained from the ROIs.

### *In vivo* cancer therapy

All procedures were conducted following a protocol approved by the National Institutes of Health Clinical Center Animal Care and Use Committee (NIH CC/ACUC). U87MG tumor-bearing mice were prepared by inoculating with U87MG cells (3×10^6^) on the flank of each female nude mouse. These mice were divided into five groups for treatment with PBS, free DOX, HPDINs, DOX loaded APDINs and THPDINs, respectively. The mice were treated with *i.v.* injection of different samples every other day for a total of three times. The tumor sizes and body weights were measured every two days, and the tumor volumes were calculated according to the formula: volume= *LW*^2^/2, (*L* and *W* refer to the length and width of the tumor, respectively).
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![**The illustration of internalization of a theranostic platform-THPDINs.** Upon internalization, low pH environment induces a protonation reaction of the HPDI, achieving simultaneously ratiometric pH imaging and DOX release monitoring.](thnov09p0526g001){#F1}

![**Characterization of the THPDINs theranostic platform. (A)** Schematic illustration of the sensing and drug releasing mechanism of THPDINs. The THPDINs is self-assembled with a pH-sensitive HPDI (green), a pH-inert IR825 (gold), and an anticancer drug of DOX (blue). At low pH, the HPDI will be protonated (pink), inducing a loosened nanostructure that could trigger the release of the encapsulated DOX accompanied by PA signals vanishing at 680 nm. Meanwhile, the chemical structure of IR825 and its characteristic PA signal at 825 nm retain the same. Therefore, the DOX release process could be monitored by a ratiometric PA imaging at PA~825~/PA~680~. **(B)** TEM images and **(C)** DLS data indicate diameters of the THPDINs in buffer solutions with different pH values.](thnov09p0526g002){#F2}

![**Characterization of the photophysical properties of the acidity-sensitive PDI structure and its based THPDINs. (A)** Chemical structure, geometry-optimized structure, and HOMO and LUMO wave functions before and after protonation of the pH-sensitive PDI (The methyl chains were modified to amide position of PDI for simplicity). **(B)** UV-vis absorption spectra variation of HPDINs and APDINs at pH 7.4 and 5.0. **(C)** UV-vis absorption spectra of THPDINs and **(D)** Release profiles of DOX from THPDINs at buffer solutions with different pH (Inset picture showed THPDINs solutions at pH 7.4 and 5.0). **(E)** Representative PA images of the THPDINs solution at 680 and 825 nm. PA specific capillary tubes loading different THPDINs solution at different pH for the PA imaging tests at 680 and 825 nm, respectively. The solutions are indicated in pseudo color. **(F)** Representative PA spectra ranging from 680 to 900 nm of the THPDINs under different pH. **(G)** Quantification of the ratiometric PA signals (PA~825~/PA~680~) of the THPDINs as a function of various pH from 4.0 to 8.0.](thnov09p0526g003){#F3}

![**Investigation of *in vitro* therapeutic effect of THPDINs. (A)** CLSM images (Scale bar, 50 µm) and **(B)** quantitative DOX intensities of the U87MG cells incubated with the THPDINs for 0.5, 2 and 6 h. **(C)** Cytotoxicity of U87MG cells with different treatments: THPDINs with various DOX concentration. **(D)** The apoptosis of U87MG cells analyzed by flow cytometry, the cells were treated with THPDINs in various DOX concentration (0, 0.3125, 1.25, 5, 20 µM).](thnov09p0526g004){#F4}

![***In vivo* PA imaging of tumor pH. (A)** Representative PA images of a subcutaneous U87MG tumor in a nude mouse after intravenous administration of the THPDINs at post-injection time 0, 4, 24, 48 h. **(B)** Quantification of the PA intensity increment at 680 (∆PA~680~) and 825 nm (∆PA~825~) as a function of the post-injection time of the THPDINs. **(C)** Ratiometric PA signals (∆PA~825~/∆PA~680~) as a function of post-injection time. The error bars showed three separate standard PA tests (n = 3).](thnov09p0526g005){#F5}

![***In vivo* cancer therapeutic efficacy of theranostic platforms. (A)** Xenograft U87MG tumor volume growth curves in different treatment groups: PBS, free DOX, HPDINs, DOX loaded APDINs and THPDINs. **(B)** The survival rate curves of the treated mice with various treatments of PBS, free DOX, HPDINs, DOX loaded APDINs and THPDINs. **(C)** Representative photographs of tumor bearing mice, resected U87MG tumors (scale bar, 0.5 cm), and H&E stained images (Scale bar, 0.1 cm) in different treatment groups on day 18. Compared with the control groups, the tumor treated by THPDINs showed strong therapeutic efficacy. \*\*\*, P \< 0.001.](thnov09p0526g006){#F6}
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